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Background: microRNAs are small noncoding RNAs that modulate a variety of cellular processes by regulating
multiple targets, which can promote or inhibit the development of malignant behaviors. Accumulating evidence
suggests miR-24 plays important roles in human carcinogenesis. However, its precise biological role remains largely
elusive. This study examined the role of miR-24 in gastric cancer (GC).
Methods: The expression of miR-24 in GC tissues compared with matched non-tumor tissues and GC cells was
detected by qRT-PCR. Synthetic short single or double stranded RNA oligonucleotides and lentiviral vectors were
used to regulate miR-24 expression in GC cells to investigate its function in vitro and in vivo.
Results: miR-24 was significantly downregulated in GC tissues compared with matched non-tumor tissues and was
associated with tumor differentiation. Ectopic expression of miR-24 in SGC-7901 GC cells suppressed cell proliferation,
migration and invasion in vitro as well as tumorigenicity in vivo by inducing cell cycle arrest in G0/G1 phase and
promoting cell apoptosis. Furthermore, we identified RegIV as a target of miR-24 and demonstrated that miR-24
regulated RegIV expression via binding its 3′ untranslated region.
Conclusions: miR-24 functions as a novel tumor suppressor in GC and the anti-oncogenic activity may involve its
inhibition of the target gene RegIV. These findings suggest the possibility for miR-24 as a therapeutic target in GC.
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Gastric cancer (GC) is one of the most common human
cancers. Although the incidence and mortality have
decreased worldwide over the past 20 years, GC still
ranks as the fourth most common and the second most
lethal cancer worldwide [1]. Although research in GC
has made great progress, the molecular mechanisms
underlying GC still have not been fully elucidated.
MicroRNAs (miRNAs) are small noncoding, double-
stranded RNA molecules that can modulate the expres-
sion of target genes by influencing the post-transcriptional
processes regulating gene expression. miRNAs recognize
target mRNAs based on complete or incomplete sequence
complementarity and prevent the production of protein* Correspondence: byliu@sjtu.edu.cn; yangqiumeng@hotmail.com
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unless otherwise stated.by binding to the 3′ untranslated region (UTR) or the
open reading frame (ORF) of target mRNA [2,3]. miRNAs
have been demonstrated to function in cellular proli-
feration and differentiation processes, including the
epithelial-mesenchymal transition [4] and endodermal
differentiation of human embryonic stem cells [5]. In
addition to general cellular functions of miRNA, these
molecules also play important roles in a variety of
human diseases. Multiple studies have shown that the
misregulation of miRNAs is related with cancer [6,7],
in which they function as either oncogenes or tumor
suppressors. miRNAs have been reported to be involved
in acute myeloid leukemia, breast cancer, non-small cell
lung carcinoma, hepatocellular carcinoma, colon cancer,
GC and other cancers [8-13]. Overexpression or down-
regulation of miRNAs leads to diversification of protein
expression, therefore contributing to tumorigenesis by
modulating proliferation, angiogenesis and invasion.
Researchers found that miRNA expression profiles cantd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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prior to the use of messenger RNA profiles for classifi-
cation of poorly differentiated tumors [14,15].
Aberrant expression of specific miRNAs in GC has
been previously reported and was correlated with the
progression and prognosis of GC [16-18]. We previously
found that miR-24, which can serve as a tumor sup-
pressor through a target site polymorphism [19], was a
significantly downregulated miRNA in GC cells and
tissues compared with non-tumor tissues. In this study,
we analyzed miR-24 expression levels in GC tissues
compared with matched non-tumor tissues, and assessed
correlations between miR-24 level and clinicopathologic
parameters. We evaluated the influence of overexpression
of miR-24 on the growth and apoptosis of SGC-7901 GC
cells both in vitro and in vivo. We also determined the
biological effect of downregulation of miR-24 expression
on GC cells. Furthermore, we identified RegIV (regenerat-
ing islet-derived family, member 4) as one of the target
genes of miR-24. We hypothesize that miR-24 can regulate
the invasion and metastasis of GC cells by directly target-
ing the RegIV gene.
Results
Overexpression of miR-24 inhibits GC cell proliferation
To explore the expression of miR-24 in GC, quantitative
real-time RT-PCR (qRT-PCR) was performed. Expres-
sion of miR-24 was generally downregulated in nine GC
cell lines compared with the immortalized normal gastric
mucosal epithelial cell GES-1 (Figure 1A). Expression of
miR-24 was examined further with qRT-PCR in tumor
tissues and matched non-tumor tissues from 63 GC
patients (Figure 1B). The average expression level of
miR-24 was significantly downregulated in tumor tissues
compared to matched non-tumor tissues (Figure 1C).
Together, these results provided strong evidence that miR-
24 was significantly downregulated in GC.
We next examined the correlations between expres-
sion level of miR-24 and clinicopathologic factors in
human GC. The clinical and pathologic characteristics
of 63 GC patients are provided in Table 1. Based on rela-
tive expression ratios of miR-24/U6 = 1, the cases were
divided into two groups: the miR-24 high-expression
group (n = 29) and the miR-24 low-expression group
(n = 34). The miR-24 low-expression group exhibited
significantly lower tumor differentiation (P = 0.021).
However, the miR-24 expression level did not show any
relationship with age, gender, tumor site, the depth of local
invasion, lymph node metastasis, or TNM stage.
To investigate the biological function of miR-24 in
development and progression of GC, we transfected
SGC-7901 cells with miR-24 mimics (SGC-7901/miR-24)
or miR-24 inhibitor (SGC-7901/anti-miR-24). As shown
in Additional file 1: Figure S1A and S1B, we selected100 nM as suitable concentration in subsequent experi-
ments. Ectopic expression of miR-24 in SGC-7901 cells
was confirmed by qRT-PCR. Next, we examined cell
proliferation by WST assay. Overexpression of miR-24
inhibited the growth rate of SGC-7901 cells compared
with miR-control transfected cells (P < 0.05), whereas
anti-miR-24 increased cell growth activities (P < 0.05,
Figure 1D).Overexpression of miR-24 inhibits the migration and
invasion of GC cells
Next we evaluated the effect of miR-24 on cell migra-
tion and invasion in GC. Cell migration and invasion
assays showed that overexpression of miR-24 sup-
pressed cell migration (SGC-7901/miR-24 group, 63.0
± 3.6 cells per field; control group, 126.3 ± 7.0 cells per
field; P < 0.05) and invasion (SGC-7901/miR-24 group,
34.7 ± 2.1 cells per field; control group, 63.7 ± 3.5 cells
per field; P < 0.05) (Figure 2A,B). In contrast, knock-
down of miR-24 significantly increased cell migration
(SGC-7901/anti-miR-24 group, 182.3 ± 5.0 cells per
field; control group, 105.3 ± 3.8 cells per field; P < 0.01)
and invasion (SGC-7901/anti-miR-24 group, 124.3 ±
3.8 cells per field; control group, 62.7 ± 2.5 per field;
P < 0.01) (Figure 2A,C).Overexpression of miR-24 promotes the apoptosis of GC
cells and induces cell cycle arrest in G0/G1 phase
Given that observed cellular growth may be affected by
the rates of apoptosis and cell cycle progression, we ex-
amined the effects of miR-24 on apoptosis and cell cycle
in vivo by flow cytometry. We found that approximately
12–15% of SGC-7901/miR-24 cells exhibited morpho-
logic features typical of apoptosis, including condensed
chromatin and nuclear fragmentation by Hoechst33342
staining for DNA content. In contrast, after accounting
for the rare spontaneous apoptosis in SGC-7901 cells,
the SGC-7901/anti-miR-24 group did not show any sig-
nificant changes by Hoechst33342 staining (Figure 3A).
Flow cytometry showed that the apoptotic rate was
significantly increased in SGC-7901/miR-24 cells com-
pared with control cells (13.62% ± 1.25% vs. 6.15% ± 0.95%,
respectively; P < 0.01), and significantly decreased in SGC-
7901/anti-miR-24 compared with controls (3.92% ± 0.52%
vs. 6.35% ± 0.83%, respectively; P < 0.05) (Figure 3B,D).
To further elucidate the mechanism of miR-24-mediated
growth inhibition of GC cells, cell cycle analysis was per-
formed (Figure 3C,E). Upon upregulation of miR-24, the
percentage of cells in G0/G1 phase increased from
40.51% ± 3.15% in controls to 72.24% ± 3.65% (P < 0.01),
while knockdown miR-24 reduced the percentage of
cells in G0/G1 phase from 42.35% ± 2.78% in controls to
30.25% ± 1.25% (P < 0.05).
Figure 1 miR-24 is significantly downregulated in GC and inhibited SGC-7901 cell growth. (A) Relative expression of miR-24 in nine GC cell
lines compared with GES-1 determined by qRT-PCR of three independent experiments (**P < 0.01, ***P < 0.001). (B) Relative expression of miR-24
in surgical specimens of 63 GC determined by qRT-PCR. All experiments were performed in triplicate. Data are shown as -ΔΔCT values, S.D. not
shown. (C) The mean and standard deviation of miR-24 expression levels in surgical specimens of 63 GC tissues and matched non-tumor tissues
are shown. Data are presented as 2-ΔCT values (**P < 0.05). U6 snRNA was used for normalization. (D) miR-24 inhibited the growth of SGC-7901
cells as detected by WST, while anti-miR-24 increased cell growth (*P < 0.05). Data are shown as mean ± S.D. of three independent experiments.
Duan et al. Molecular Cancer 2014, 13:127 Page 3 of 13
http://www.molecular-cancer.com/content/13/1/127RegIV is a target gene of miR-24
To more closely examine the mechanisms of miR-24 in
GC, we searched for candidate target genes by bioinfor-
matics. TargetScan, miRBase Tatget and StarBase were
applied to search for potential targets of miR-24. Among
the predicted targets, RegIV was identified as one of the
target genes of miR-24, and we identified one potential
miR-24 binding site within its 3′UTR (Figure 4A). Next, we
examined the expression of RegIV in nine GC cells and
GES-1. We found that RegIV was overexpressed in nineGC cells compared with GES-1, and exhibited an inverse
expression pattern compared with miR-24 (Additional
file 2: Figure S2A and S2B). To investigate whether the
3′UTR of RegIV mRNA was a functional target of miR-
24, luciferase reporter gene assays were performed. We
first evaluated the activity of miR-24 (or miR-control)
co-transfected into SGC-7901 cells with Luc-RegIV
plasmid or the Luc-RegIV-mut plasmid (in which the
putative miR-24 binding site was mutated), along with
the pRL-TK plasmid containing the Renilla luciferase
Table 1 Relationship between miR-24 expression level




valueHigh (n = 29) Low (n = 34)
Gender
Male 17 21 0.799
Female 12 13
Age (years)
<60 15 18 0.923
≥60 14 16
Tumor location
Distal third 8 8 0.310
Middle third 6 13
Proximal third 15 13
WHO classification
Adenocarcinoma 25 28 0.155
Signet-ring cell carcinoma 1 5
Mucinous adenocarcinoma 3 1
Differentiation
Well, moderately 15 8 0.021
Poorly 14 26
Borrmann classification
I/II 11 12 0.828
III/IV 18 22
Local invasion
T1/T2 1 7 0.098
T3/T4 28 27
Lymph node metastasis
No 6 4 0.535
Yes 23 30
Distant metastasis
No 28 31 0.724
Yes 1 3
TNM stage
I/II 7 8 0.955
III/IV 22 26
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with miR-24 demonstrated a significant decrease of
luciferase activity compared with the miR-control group
(P < 0.05). However, miR-24 co-transfected with the
Luc-RegIV-mut plasmid showed no significant difference
in reporter activity compared with cells co-transfected
with miR-control. Likewise, anti-miR-24 increased the
luciferase activity of wild-type Luc-RegIV, but had no
effect on Luc-RegIV-mut plasmid (Figure 4C; P < 0.05).
We also performed luciferase reporter gene assays inSNU-16 to minimize the influence of endogenous miR-
24. At first, ectopic expression of miR-24 in SNU-16
cells was confirmed by qRT-PCR. Expression of miR-24
transfected with miR-24 mimics was about 50 times higher
than that of miR-control group in SNU-16 (P < 0.01), while
no statistical difference with the transfection of anti-miR-24
(Additional file 3: Figure S3A). Cells co-transfected with
miR-24 demonstrated a significant decrease of lucifer-
ase activity compared with the miR-control group (P <
0.001), while no statistical difference with anti-miR-24
transfection (Additional file 3: Figure S3B and S3C).
These results strongly indicated that the 3′UTR of
RegIV contains direct binding sites for miR-24.
Next we examined miR-24 regulation of RegIV mRNA
and protein levels in transfected SGC-7901 cells. ELISA
analysis showed that RegIV protein levels were greatly
suppressed in SGC-7901/miR-24 cells, whereas RegIV
protein levels were upregulated in SGC-7901/anti-miR-24
cells (Figure 4D; *P < 0.05, **P < 0.01). qRT-PCR analysis
indicated no difference in the level of RegIV mRNA in all
transfected cell groups (Figure 4E; P > 0.05). Meanwhile,
we detected the expression of c-MYC in GC cells as
positive control transfected with miR-24 [20]. We found
that miR-24 downregulated RegIV and c-MYC (Additional
file 4: Figure S4A and S4B).
Previous studies demonstrated that RegIV was associ-
ated with proliferation and metastasis of GC. We next
used immunohistochemical analysis to evaluate the
expression of RegIV in GC. Our findings confirmed
overexpression of RegIV in GC. The protein level of
RegIV in normal gastric mucosa was lower than intes-
tinal metaplasia of stomach and gastric signet-ring cell
carcinoma (Figure 4F–H). To assess the clinical relevance
of these findings, we examined the correlation between
the expressions of RegIV and miR-24 in GC tissues. We
found that RegIV and miR-24 exhibited an inverse expres-
sion pattern in GC tissues (Table 2). These results support
the notion that downregulation of miR-24 resulted in
increased protein levels of RegIV in GC.
Overexpression of miR-24 inhibits tumorigenicity in vivo
Given that miR-24 improved the proliferation of GC
cells in vitro, we examined whether miR-24 could affect
tumorigenicity in vivo. Retrovirus-mediated SGC-7901/
miR-24 and SGC-7901/miR-control stable cell lines
were obtained as described in the Methods section.
SGC-7901/RV-miR-24 and SGC-7901/RV-miR-control
cells were injected subcutaneously into four-week-old male
nude mice, and tumor formation was monitored. Tumors
grew slower in the SGC-7901/RV-miR-24 group than those
in the SGC-7901/RV-miR-control group (Figure 5A). The
average tumor volume in mice inoculated with SGC-7901/
RV-miR-24 cells at day 28 was significantly smaller com-
pared to mice inoculated with SGC-7901/RV-miR-control
Figure 2 miR-24 inhibited migration and invasion of SGC-7901 cells. (A) Representative fields of SGC-7901 cells in the transwell assays. (B, C)
Representative fields of SGC-7901 cells in the migration and invasion assays, respectively. Average number of migration and invasion cells per field
from three independent experiments (*P < 0.05, **P < 0.01).
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respectively) (Figure 5B and C; P < 0.05).
To assess whether tumor growth inhibition in SGC-
7901/RV-miR-24 cells was partly due to the suppression
of proliferation, immunohistochemical analyses of tumor
tissues were performed. As shown with Ki-67 antigen
staining, the decreased tumor growth in mice injected
with SGC-7901/RV-miR-24 cells may be partially because
of lower proliferation caused by the overexpression of
miR-24. The percentage of Ki-67-antigen-positive cells
was lower in the tumor derived from SGC-7901/RV-miR-
24 cells than the tumor derived from SGC-7901/RV-miR-
control cells (37.1% ± 3.6% vs. 79.5% ± 5.2%, respectively)
(Figure 5D and E; P < 0.01). The expression level of RegIV
as determined by ELISA was lower in the tumor derived
from cells overexpressing miR-24 than the tumor derived
from control cells (1.77 ± 0.15 ng/ml in SGC-7901/RV-
miR-24 vs. 3.13 ± 0.25 ng/ml in SGC-7901/RV-miR-
control) (Figure 5F; P < 0.05). However, there was nostatistical difference in the relative expression of RegIV
mRNA (Figure 5G). Therefore, the tumorigenicity of SGC-
7901/RV-miR-24 cells were significantly reduced in vivo.
Discussion
Accumulating evidence has supported important roles for
miRNAs, which act either as tumor suppressors or onco-
genes, in GC [21-23]. In addition, many miRNAs have
been shown to exhibit therapeutic potential. Because of
their function as master regulators of the genome and
novel mechanism of action, miRNAs are considered a
promising technology for therapeutic development [24].
miR-26a has antitumorigenic properties and potential
therapeutic utility for liver cancer in vitro and in vivo, and
was associated with rapid and sustained inhibition of can-
cer cell proliferation and highly specific induction of
tumor cell death [25]. The specific mechanism of the roles
of dysregulated miRNAs in gastric carcinogenesis remains
elusive.
Figure 3 miR-24 induced cell apoptosis and G0/G1 cell cycle arrest. (A) Representative histograms depicting nuclear morphology of
SGC-7901 cells transiently transfected with 100 nM miR-24 mimics or inhibitor and their respective controls (Hoechst33342 staining, original
magnification 400×). (B) Representative histograms depicting apoptosis of SGC-7901 cells transiently transfected with 100 nM miR-24 mimics or
inhibitor and their respective controls. (C) Representative histograms depicting cell cycle of SGC-7901 cells transiently transfected with 100 nM miR-24
mimics or inhibitor and their respective controls. (D, E) The percentage of apoptotic and G0/G1 phase cells of three independent experiments,
mean ± S.D. (*P < 0.05, **P < 0.01).
Duan et al. Molecular Cancer 2014, 13:127 Page 6 of 13
http://www.molecular-cancer.com/content/13/1/127
Figure 4 (See legend on next page.)
Duan et al. Molecular Cancer 2014, 13:127 Page 7 of 13
http://www.molecular-cancer.com/content/13/1/127
(See figure on previous page.)
Figure 4 miR-24 targeted the 3′UTR of RegIV gene and immunostaining of RegIV in gastric tissues. (A) Schematic graph of the putative
binding sites of miR-24 in the RegIV 3′UTR. RegIV-mut indicates the RegIV-3′UTR with mutation in miR-24-binding sites. (B) miR-24 mimics
downregulated activity of a luciferase reporter containing wild-type RegIV 3′UTR (*P < 0.05), but not the reporter with mutant RegIV 3′UTR.
(C) Anti-miR-24 increased the luciferase activity of wild-type Luc-RegIV (*P < 0.05), but had no effect on the mutant. (D) Forty-eight hours after
miR-24 mimic and control transfection of SGC-7901 cells, the protein level of RegIV was significantly decreased compared with the miR-control
as determined by ELISA. Anti-miR-24 increased the expression of RegIV compared with the anti-miR-control (*P < 0.05, **P < 0.01). (E) Twenty-four hours
after miR-24 mimic or inhibitor and the respective control transfection in SGC-7901 cells, there was no difference in the mRNA level of RegIV
compared with the miR-control as determined by qRT-PCR (P > 0.05). Data are shown as mean ± S.D. of three independent experiments. (F) No
expression of RegIV was detected in normal gastric mucosa. (G) RegIV was expressed in intestinal metaplasia of stomach. (H) Strong expression
of RegIV was observed in gastric signet-ring cell carcinoma.
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miR-24 on tumor metastasis at the clinical, cellular and
molecular level and in an experimental animal model.
We provided detailed mechanistic experimental evidence
for the role of miR-24 in GC by suppressing the expres-
sion of RegIV. Studies showed that miR-24 may act as
oncogene in malignant effusions [26], oral carcinoma
[27,28], prostate cancer [3] and lung cancer [29,30], but
may act as a tumor suppressor in colon cancer [19] and
retinoblastoma tumors [31]. Lal A et al. found that miR-
24 inhibited cell proliferation and cell cycle progression
by suppressing the expression of E2F2, MYC and other
cell cycle regulatory genes by binding to “seedless” 3′
UTR miRNA recognition elements [20]. Wu J et al. re-
ported that transfection of miR-24 into GC cells reduced
the expression of AE1 protein, which resulted in inhibit-
ing cellular proliferation [32]. However, the complete
underlying mechanisms for miR-24 in GC are still not
clear.
Our report identified miR-24 as a candidate tumor
suppressor in GC. We found downregulation of miR-24
expression both in GC tissues and cell lines. Overex-
pression of miR-24 in SGC-7901 GC cells significantly
reduced proliferation and invasion both in vitro and
in vivo, revealing the potential therapeutic effect of miR-
24 in GC. The opposite result was obtained when the
expression of miR-24 was inhibited by anti-miR-24. To-
gether these results suggest that miR-24 may function as
a tumor suppressor in human GC.
miRNAs bind to perfect or imperfect complementary
“seed” sequences in target mRNAs, leading to cleavageTable 2 RegIV and miR-24 exhibit inverse expression
pattern in GC
miR-24 expression P value
Low High
Reg IV (IHC)
Negative 9 16 0.038*
Positive 25 13
*P <0.05 was considered statistically significant.of target mRNAs or inhibition of their translation [33].
In this study, we identified RegIV as a target gene of
miR-24. miR-24 bound with incomplete complementarity
to RegIV mRNA, resulting in direct translational inhibition
of RegIV mRNA but with no effect on overall mRNA sta-
bility. As the different action modes of miRNA, miR-24 did
not affect the mRNA level of RegIV but the translational in-
hibition. RegIV is a member of the human Reg gene family,
which shares sequence similarity with the carbohydrate-
binding domain of C-type lectins, and was first isolated and
characterized in human inflammatory bowel disease [34].
RegIV is one type of secreted proteins, and plays a bio-
logical role depending on the extracellular secreted pro-
teins, so that we took ELISA as a preferred detection
method. Western blot was also performed to validate
the protein level of RegIV, and we obtained the similar
results. Previous studies have reported that the RegIV
gene was frequently overexpressed in GC and is poten-
tially involved in invasion, metastasis, and carcinogen-
esis of GC. RegIV expression was narrowly restricted
in noncancerous tissues [35,36]. RegIV expression was
markedly higher in patients with peritoneal metastasis
compared to those without peritoneal metastasis.
RegIV might accelerate peritoneal metastasis in GC
and levels in lavage fluids could serve as a good marker
for peritoneal metastasis [37-39]. RegIV may function
as a serum biomarker for GC patients and inhibits 5-
FU-induced apoptosis by induction of Bcl-2 and dihy-
dropyrimidine dehydrogenase [40].
In the current study, we identified miR-24 as a poten-
tial upstream regulator of RegIV. First, overexpression of
miR-24 decreased the activity of a luciferase reporter
gene containing the 3′UTR of RegIV, while mutation of
the “seed region” sites in the 3′UTR of RegIV abolished
the regulatory effect of miR-24. The opposite result was
obtained when we used anti-miR-24. Second, human GC
tissues expressed significantly lower levels of miR-24
than non-tumor tissues, while GC tissues contain signifi-
cantly higher levels of RegIV protein than non-tumor
tissues. Third, overexpression of miR-24 downregulated
RegIV at the protein level, while downregulation of miR-
Figure 5 miR-24 inhibited tumorigenicity and proliferation in vivo. (A) Photograph of tumors derived from RV-miR-24 or RV-miR-control
cells in nude mice. (B) Growth kinetics of tumors in nude mice. Tumor diameters were measured every 7 days. The volume of the nude mice
indicated by bars, S.D. (*P < 0.05). (C) The average weight of tumors in nude mice. Data are shown as means ± S.D. (*P < 0.05). (D) Representative
photographs of immunohistochemical analysis of Ki-67 antigen in tumors of nude mice (original magnification, 200×). (E) Representative proliferative
index of tumors in RV-miR-24 and RV-miR-control nude mice. Data are shown as means ± S.D. (**P < 0.05). (F) Expression levels of RegIV in tumor tissues
of nude mice. Data are shown as means ± S.D. (*P < 0.05). (G) Expression levels of RegIV mRNA in tumor tissues of nude mice (P > 0.05). Data are shown
as mean ± S.D. of three independent experiments.
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of miR-24 was significantly related with proliferation and
metastasis, indicating a functional overlap with RegIV. All
these results indicate that RegIV might be a direct target
gene of miR-24 in GC.
Carcinogenesis is a series of sequential events, includ-
ing detachment, migration, local invasion, angiogenesis,
intravasation, survival in the circulatory system, extrava-
sation and regrowth in different organs [41,42]. Here we
showed that miR-24 could regulate the carcinogenesis of
GC through modulating proliferation, migration and
local invasion. Furthermore, our evidence suggests the
possibility for miR-24 as a therapeutic target in GC. Fur-
ther studies are required to fully understand the detailed
mechanisms of miR-24 in GC carcinogenesis and as a
potential therapeutic approach.Methods
Ethical statement
Written informed consent was collected from all partici-
pants, and study protocol was approved by the ethics
committee of Ruijin Hospital, Shanghai Jiaotong Univer-
sity School of Medicine. All mouse experiments were
approved by the Animal Care (Permit#20120810) and
Use Committee and conducted in accordance with the
official recommendations of the Care and Use Labora-
tory Animals of Ruijin Hospital, Shanghai Jiaotong Uni-
versity School of Medicine.
Cell lines
The human GC cell lines SNU-1, SNU-16, NCI-N87,
and KATO III were purchased from American Type
Culture Collection (ATCC). The cell lines SGC-7901,
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from Shanghai Institutes for Biological Sciences, Chinese
Academy of Sciences. The immortalized normal gastric
mucosal epithelial cell line (GES-1) was a gift from Prof.
Feng Bi (Huaxi Medical University, Chengdu, Sichuan
Province, PR China). The embryonic kidney cell line 293 T
was preserved in our laboratory and maintained in
Dulbecco’s modified Eagle’s medium (DMEM) with
10% fetal bovine serum (FBS) at 37°C in a humidified
atmosphere with 5% CO2. All GC cells were cultured in
RPMI 1640 supplemented with 10% FBS in a humidi-
fied incubator with 5% CO2 at 37°C.
Tissue samples
Primary cancer tissues and paired adjacent non-tumor
tissues were collected from patients with GC under-
went radical gastrectomy at the Department of Surgery,
Ruijin Hospital, Shanghai Jiao Tong University School
of Medicine. The adjacent normal tissues were obtained
over 5 cm from the primary cancer. Tissue samples were
immediately snap-frozen in liquid nitrogen and stored
in a refrigerator at −80°C. Tissues for immunohisto-
chemistry were fixed in 4% paraformaldehyde and paraffin-
embedded. Clinicopathological data were reviewed,
and TNM staging classification was based on criteria
of American Joint Committee on Cancer (AJCC, 6th
edition). All samples were verified by pathological
examination.
RNA isolation and qRT-PCR
Total RNA was isolated from tissue samples and cell lines
using Trizol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. The ex-
pression levels of miRNAs were evaluated using the
Hairpin-itTM miRNAs qPCR Quantitation Kit (Gene-
Pharma, Shanghai, PR China) following the manufac-
turer’s protocol. The U6 small nuclear RNA (RNU6B;
GenePharma) was used for normalization. The relative
expression ratio of miR-24 in each paired tumor and
non-tumor tissue was calculated using the 2-ΔΔCT method.
The miR-24 expression level was defined as upregulated
when the relative expression ratio was >1, and defined
as downregulated when the relative expression ratio
was <1. The expression level of RegIV and c-MYC
mRNA was measured by qRT-PCR according to the
instructions of the SYBR® Green PCR Master Mix (Ap-
plied Biosystems, Foster City, CA, USA). The primers for
RegIV were 5′- CACGACCCACAGAAGAGGCAGC −3′
(forward) and 5′- GGCGCTTGTTGCATTCGTTGCT −3′
(reverse). Primers for c-MYC were 5′- TCTTCCCC
TACCCTCTCAACGA −3′ (forward) and 5′- TTCCT
CATCTTCTTGTTCCTCCTCA −3′ (reverse). Primers
for GAPDH were 5′- GGACCTGACCTGCCGTCTA
G −3′ (forward) and 5′- GTAGCCCAGGATGCCCTTGA −3′ (reverse) according to the human RegIV,
c-MYC and GAPDH cDNA sequences in GenBank. The
GAPDH mRNA level was used for normalization. PCRs
of each sample were conducted in triplicate.
Transient transfection
The hsa-miR-24 mimics (miR-24), negative control
(miR-control), hsa-miR-24 inhibitor (anti-miR-24) and
inhibitor negative control (anti-miR-control) oligonu-
cleotides were purchased from GenePharma. Cells in
logarithmic growth phase were trypsinized, counted,
and seeded in 6-well plates to ensure 50% cell confluence
on the next day for transfection. Transfection of cells with
oligonucleotides was performed using Lipofectamine™
2000 Reagent in line with the manufacturer’s instructions
(Invitrogen) at a final concentration of 100 nM.
ELISA
ELISA (Cusabio, Wuhan, China) analysis of RegIV was
performed 48 h post-transfection with miR-24 oligonu-
cleotides. The culture supernatants were collected, and
the secreted RegIV level was quantified by ELISA ac-
cording to the manufacturer’s protocol. The expression
of RegIV in tumor tissues was detected by ELISA.
Cell proliferation assay
SGC-7901 cells proliferation was measured by the col-
orimetric water-soluble tetrazolium salt (WST) assay
with a Cell Counting Kit-8 according to the manufac-
turer’s instructions (Dojindo, Kumamoto, Japan). The
cells were seeded in 96-well plates (2 × 103 cells/well)
24 h post-transfection, and cell proliferation was exam-
ined every 24 h for 5 days. The number of viable cells
was determined by measurement of the optical density
difference between 450 nm and 600 nm using a Safire2
microplate reader (Tecan, Switzerland). All experiments
were performed in triplicate.
Migration and invasion assay
Migration assays were performed using the 6.5 mm
Transwell® with 8.0 μm Pore Polycarbonate Membrane
Insert (Corning, New York, USA) according to the man-
ufacturer’s instructions. At 24 h post-transfection with
miR-24 mimics, inhibitors and controls (100 nM), SGC-
7901 cells were incubated in serum-free medium for
24 h, and then 3 × 104 cells in 200 μl serum-free medium
were added to the upper chamber. A volume of 500 μl
of 10% FBS-containing medium was then added to the
lower chamber as a chemoattractant. Cells were incu-
bated for another 36 h at 37°C, and then non-migrating
cells on the upper surface of the membrane were gently
scraped off with cotton swabs. Cells that migrated to the
bottom of the membrane were stained with the cell stain
provided in the assay kit for 20 min and visualized under
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domly selected fields with 200× magnification were
counted, and the average number was taken.
For the invasion assay, 6.5 mm Transwell® with 8.0 μm
Pore Polycarbonate Membrane Insert (Corning) was
used according to the manufacturer’s instructions and
matrigel (BD Biosciences, USA) was used to simulate
the extracellular matrix in vivo. Briefly, 3 × 104 SGC-
7901 cells in 200 μl serum-free medium were added to
the upper chamber pre-coated with matrigel gel. Then,
500 μl of 10% FBS-containing medium was added to the
lower chamber as a chemo-attractant. Cells were incu-
bated for 48 h at 37°C, and then non-invading cells were
removed with cotton swabs. Invasive cells were fixed,
stained with 0.04% crystal violet and counted as de-
scribed above.
Apoptosis and cell cycle analysis
At 48 h post-transfection, cells were collected by tryp-
sinization and washed with PBS. For apoptosis analysis,
cells were resuspended in Binding Buffer (Annexin V-FITC
Apoptosis Detection Kit I, BD Pharmingen, USA) at a
concentration of 1 × 106 cells/ml. Next, 2.5 μl of FITC
AnnexinV and 5 μl PI (BD Pharmingen) were added to
100 μl of the cell suspension. After incubation for
15 min in the dark at room temperature, 400 μ1 binding
buffer was added. Apoptosis was analyzed by flow
cytometry (FACSCalibur, Becton Dickinson) using Cell
Quest software (Becton Dickinson). Annexin V-FITC-
positive and PI-negative cells were detected as undergo-
ing apoptosis.
For cell cycle analysis, the cells were fixed with 70%
ethanol and stored at 4°C overnight. The following day,
the fixed cells were washed with PBS, treated with 2 μl
of RNase A (50 μg/ml), and stained with 20 μl of Propi-
dium Iodide (50 μg/ml) for 30 min in the dark at 37°C,
with rocking every 5 min. The stained cells were ana-
lyzed by flow cytometry (FACSCalibur). At least 10000
cells in each sample were analyzed to obtain a measur-
able signal.
For examining nuclear morphology associated with
apoptosis, cells were washed in PBS and incubated with a
DNA dye, Hoechst33342 (Beyotime, Nantong, PR China),
according to the protocol of the kit. The staining was visu-
alized under a fluorescent microscope that was excited at
a wavelength of 350 nm and measured at 460 nm.
Construction of the RegIV 3′UTR reporter gene system
A 600 bp fragment of the wild-type (WT) RegIV-3′UTR
or mutant RegIV-3′UTR (mut) containing the putative
miR-24 binding site was synthesized by RT-PCR. The
wild-type RegIV-3′UTR was synthesized using the
following sequences: 5′- ggactagtagcaagaatcaagattctgc
taact −3′ (forward) and 5′- cgacgcgttgggtgtatttcttggtcttatttc −3′ (reverse). The mutant RegIV-3′UTR was
designed to mutate three intermittent nucleotides com-
plementary to the miR-24 seed region. The mutant
sequences were as follows: 5′- gaggttgctgagatgcagttcag
taatggtgaatgtggaa −3′ (forward) and 5′- ttccacattcaccat-
tactgaactggaacacagcaacctc −3′ (reverse). After digestion
with SpeI and MluI, the wild-type and mutant RegIV-3′
UTR fragments were cloned into the SpeI and MluI
sites of the pMIR-Report luciferase vector (Applied Bio-
systems) and named pMIR/RegIV and pMIR/RegIV/
mut, respectively. Proper insertion was confirmed by
sequencing. SGC-7901 cells were seeded in 24-well
plates. At 24 h later, cells were transfected with 200 ng
of either pMIR/RegIV or pMIR/RegIV/mut, together
with 2 ng of the pRL-TK vector (Promega, Madison,
WI, USA) containing Renilla luciferase and 60 pmol of
the miR-24 mimic, inhibitor or control. Transfection
was performed using Lipofectamine™ 2000 (Invitrogen)
and Opti-MEM I reduced serum medium. Cells were
harvested 48 h post-transfection. Firefly and Renilla
luciferase activities were measured by using a dual-
luciferase reporter assay (Promega) according to the
manufacturer’s protocol. Firefly luciferase activity was
normalized to Renilla luciferase activity.
Western blot analysis
Cells were lysed in RIPA buffer in the presence of Prote-
ase Inhibitor Cocktail (Pierce, Rockford, USA). Protein
was quantified by a BCA Protein Assay Kit (Pierce,
Rockford, USA). Protein (60 ug) was separated by 10%
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis, and transferred onto polyvinylidene fluoride mem-
branes. The membranes were blocked with 5% non-fat
milk in Tris-buffered saline and then incubated with
primary antibodies at 4°C overnight. The primary anti-
bodies used were anti-RegIV (1:1000; Abcam, USA),
anti-c-MYC (1:500; Santa Cruz Biotechnology, Inc.,
USA) and anti-β-actin (1:5000; Abcam, USA). Mem-
branes were then washed three times in TBST solution
for 10 min each time, and then incubated with second-
ary antibodies. Signals were detected by an enhanced
chemiluminescence detection system (Amersham Bio-
science, Piscataway, NJ, USA) as the manufacturer’s
protocol.
Immunohistochemistry
Paraffin sections, 4 μm in thickness, were baked for 1 h
at 68°C. After deparaffinization and rehydration, antigen
retrieval was performed by boiling in 10 mmol/l of
citrate buffer (pH 6.0) for 10 min. After inhibition of
endogenous peroxidase activity for 30 min with metha-
nol containing 0.3% H2O2, the sections were blocked
with 2% bovine serum albumin in PBS for 30 min and
incubated with mouse anti-human RegIV monoclonal
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mune complex was visualized by the Dako REAL™En-
Vision™ Detection System, Peroxidase/DAB, Rabbit/
Mouse (Dako, Denmark), according to the manufac-
turer’s procedures. The nuclei were counterstained with
hematoxylin.
Retroviral transfection for stable cell lines
The genomic region that included the primary transcript
of miR-24 was cloned into the EcoRI-XhoI site of the
modified pMSCV-GW-RfA-PGK-EGFP retroviral vector.
Negative control vectors had no insert. For each cul-
tured 293 T plate (10 cm), a plasmid mixture contain-
ing 10 μg of miR-24 retroviral vector, 10 μg of gag/pol
vector and 10 μg of VSVG vector was co-transfected
with 90 μl FuGENE6 transfection reagent (Roche, Basel,
Switzerland) added directly to 0.6 ml of serum-free
medium. The plasmid/medium/FuGENE6 mix was added
drop-wise to the 293 T plate. After 12 h, 15 ml viral
collection medium was added to the transfected cells.
We then harvested the virus twice a day for two days.
Infections of SGC-7901 cells were performed in the
presence of 8 μg/mL of polybrene in each well of a 6-well
plate. SGC-7901 cells were spin infected at 1500 rpm
for 0.5 h at room temperature and the virus-containing
supernatant was removed after 2 h. Positive cells were
selected by GFP expression by FACS and named as
RV-miR-24 or RV-miR-control. Expression of miR-24
was confirmed by qRT-PCR.
Tumor xenograft model
A total volume of 100 μl of cells (2 × 106 cells) trans-
fected with RV-miR-24 or RV-miR-control were inocu-
lated subcutaneously into 4-week-old male nude mice
(Institute of Zoology, Chinese Academy of Sciences,
Shanghai, China). Mice were checked weekly, and tumor
nodules were measured with a caliper. Tumor volume was
evaluated using the following formula: volume = (width +
length)/2 × width × length × 0.5236. Tumor growth curves
and inhibiting rates were calculated. The two experimental
groups were sacrificed after 5 weeks. All tumor grafts were
excised, weighed, harvested, fixed, and embedded. The
mouse-anti-human Ki-67 antigen monoclonal antibody
(Dako, dilution 1:50) was used to determine nuclear
expression of Ki-67 antigen with immunohistochemistry
procedures and samples were observed using a Nikon
microscope (Nikon, Japan). The proliferative index (PI)
score was measured by the mean percentage of nuclei
staining positive for Ki-67 antigen in 1000 cells.
Statistical analysis
The relationship between miR-24 expression level and
clinicopathologic parameters was explored by the Pearson
X2 test. The differences between groups were analyzedusing Student t test when there were only two groups, or
assessed by one-way ANOVA when there were more than
two groups. All statistical analyses were performed using
the SPSS 16.0 software. A two-tailed value of P < 0.05 was
considered statistically significant.
Additional files
Additional file 1: Figure S1. To validate the transfection efficiency of
miR-24 mimics and inhibitor in SGC-7901. (A) 1nM, 50 nM, 100 nM
miR-24 mimics and control transfected SGC-7901 (*P < 0.05, ***P < 0.001).
(B) 1 nM, 50 nM, 100nM miR-24 inhibitor and control transfected
SGC-7901. U6 snRNA was used for normalization. Data are shown as
mean ± S.D. of three independent experiments (**P < 0.01).
Additional file 2: Figure S2. Expression of RegIV in mRNA and protein
levels. (A) Elevated expression of RegIV mRNA in nine GC cell lines
compared with GES-1 determined by qRT-PCR. Data are shown as -ΔΔCt
values (*P < 0.05, **P < 0.01, ***P < 0.001). GAPDH was used for normalization.
(B) Elevated expression of RegIV protein in nine GC cell lines compared to
GES-1 determined by ELISA. Data are shown as mean ± S.D. of three inde-
pendent experiments (*P < 0.05, **P < 0.01, ***P < 0.001).
Additional file 3: Figure S3. miR-24 targeted RegIV in SNU-16. (A)
miR-24 expression in SNU-16 cells was effectively elevated by transient
transfection of miR-24 (miR-24 mimics), while no statistical difference by
anti-miR-24 (miR-24 inhibitor) as detected by qRT-PCR (**P < 0.01). (B)
miR-24 mimics downregulated activity of a luciferase reporter containing
wild-type RegIV 3′UTR (***P < 0.001), but not the reporter with mutant
RegIV 3′UTR. (C) Anti-miR-24 had no statistical difference on luciferase
activity of wild-type or mutant Luc-RegIV. Data are shown as mean ± S.D.
of three independent experiments.
Additional file 4: Figure S4. miR-24 downregulated c-MYC expression
in GC cell. (A) miR-24 downregulated c-MYC mRNA level in SGC-7901 and
SNU-16. Data are shown as mean ± S.D. of three independent experiments
(**P < 0.01). (B) miR-24 downregulated c-MYC and RegIV protein levels in
SGC-7901 and SNU-16.
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